NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
申请人:Boehringer Ingelheim International GmbH
公开号:US20130150401A1
公开(公告)日:2013-06-13
The present invention relates to compounds of formula I,
wherein R
1
, L
P
, L
Q
, X, A, and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.
The present invention relates to compounds of general formula I,
wherein the groups R
1
, L
Q
and Ar are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.
New compounds, pharmaceutical compositions and uses thereof
申请人:HIMMELSBACH Frank
公开号:US20130018030A1
公开(公告)日:2013-01-17
The present invention relates to compounds of general formula I,
wherein the groups R
1
, L
P
, L
Q
, X
1
, X
2
, X
3
, A, n and m are as defined in the application. The compounds of formula I have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.
4-(2,3-Dihydro-furo[2,3-c]pyridin-2-yl)-piperidine-1-carboxylic acid ester derivatives as G-protein-coupled receptor 119 (GPR119) agonists for the treatment of metabolic disorders, such as diabetes, dyslipidemia and obesity